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The current designs of new biomaterials for bone substitutes or scaffolds focus on 
achieving biocompatibility and sufficient mechanical properties. In this thesis, we investigated 
the biocompatibility of synthetic polymers called aromatic thermosetting copolyesters (ATSP) as 
potential biomaterials for bone replacements (implants). These materials are easy to manufacture 
and have good mechanical properties such as high tensile strength and high wear resistance. 
They can be made into bulk, film, foams, and composites. In this thesis, we included all these 
forms and created a composite by infusing ATSP with 10wt% of hydroxyapatite (minerals of 
similar compositions as those found in bone). Homogenous distribution of the HA filler 
improves the physical properties of composite ATSP. In addition to this, having robust adhesive 
features with metals, high energy absorption limit, and promising tribological properties makes 
ATSP a strong candidate for different orthopedic implant applications. 
This research extended an earlier biocompatibility study of ATSP in which direct contact 
of fibroblasts cells was used to study neat ATSP and ATSP blends with ultrahigh molecular 
weight polyethylene (UHMWPE) for total joint arthroplasty. The results demonstrated that cells 
were able to attach to ATSP, and there was no indication of cell death [1]. Since these previous 
results looked promising, in this thesis we conducted more extensive studies of the 
biocompatibity of ATSP.  
Chapter 1 describes the biocompatibility investigation of three different compositions 
(film, bulk, and foam) of neat and composite ATSP by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT assay) with human osteoblast cell line (hFOB 1.19 (ATCC® CRL 
11372™)), and the results were obtained from the metabolic activity of hFOB 1.19 cells for 48 
hours. The results which were either equal to or greater than 85% were accepted as non-
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cytotoxic, the values between 60% and 85% were defined as slightly cytotoxic, 30%– 59% were 
moderately cytotoxic, and less than 30% were accepted severely cytotoxic. The results of 
metabolic activity by MTT showed that each group (film, bulk, and foam) of neat and composite 
ATSP samples did not demonstrate any toxicity at all concentrations (≥85%) except for neat film 
samples which showed slight toxicity (~75%). Overall, the results for each group were consistent 
between neat and composite samples. Furthermore, the increase in the concentration did not 
change the results. The presence of HA was used to investigate the effect of HA on increasing 
the metabolic cell activity; however, there was no increase in cell activity with the presence of 
the HA. 
 Chapter 2 highlights the neat and composite foams that were designed to analyze the 
effect of biomaterial physical features, including porosity and mineral content over the bone 
formation by human mesenchymal stem cells differentiation. The analysis was done by 
alamarBlue® and RT-PCR assays. The metabolic activity results of foam samples by 
alamarBlue® with MSCs showed that none of the samples demonstrated any toxic effect; the 
metabolic activity for all samples was higher than initial metabolic activity values. All samples 
allowed cell proliferation and cell growth. Also, not only mineralized samples but also 
osteogenic media positively affected the metabolic activity because the composite samples 
showed higher metabolic activity than neat samples on the day seven. Also, samples in 
osteogenic media demonstrated the high metabolic activity in comparison with samples in 
growth media on day seven. RT-PCR results showed that the samples in osteogenic media 
showed upregulated pattern for all gene expressions. It could also be interpreted that neat and 
mineralized samples in combination with pure osteogenic media promoted osteogenesis and 
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CHAPTER 1: INTRODUCTION  
1.1 Introduction 
 
Synthetic materials have been used in the human body in previous studies. Polymer-
based synthetic biomaterials have been progressively used in various therapeutic applications 
(mostly either as substitution or restoration of tissues and organs) because of their structural and 
mechanical properties [2]. They can also be engineered into different forms, shapes, and 
structures [3,4]. Besides, physical, chemical, and biological properties of synthetic polymers can 
be tuned to match the requirements of specific applications [5]. The adaptability of these 
polymers allows the design of new materials, structures and different forms with a variety in 
porosity, pore sizes, and mechanical properties. Also, engineered polymers can be effectively 
scaled-up compared to conventional polymers. Even though synthetic polymers do not have a 
functional group for stimulation of cell adhesion, they can bind to bioactive particles, such as 
hydroxyapatite (HA) or protein sequences, to activate particular cell reactions. [6] Therefore, 
synthetic polymers for biomedical applications have outweighed natural polymers and other 
bone substitute materials. However, broad biocompatibility assays of new materials should be 
performed, and new synthetic materials should be biocompatible for medical applications, with 
an absence of immunogenic reaction. Neither the polymer nor its degradation products should 
cause irritation or toxicity in-vivo because they can cause delivery of toxic chemicals. These 
chemicals may damage the cells in the neighboring tissue and affect negatively human health [7].  
1.2 Biomaterials 
The field of biomaterial is an interdisciplinary subject based on the engineering, 
pharmaceutical, physical, and biological sciences [8]. In general, biomaterials are characterized 
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as any synthetic or natural substance, aside from nourishments and vitamins, which are suitable 
for utilization as a framework for treatment or substituent for any tissue and organ. Biomaterials 
need to fulfill various essential criteria before they can be utilized as a part of biomedical 
applications. Hence, biomaterials should be subjected to multiple tests as prescribed by different 
associations and protocols. These tests should be done to determine the proper utilization of 
materials and also decide their safety level for clinical applications in people [9]. 
 
Figure 1.1 The structure of the discipline of biomaterials [10] 
1.2.1 Concept of Biomaterials 
Biomaterials began to be used inside the body in the mid-1970s. In the early 
investigations of the biomaterial for biomedical applications, the primary focus was to analyze 
the interface between the patient and the implant considering the material effect on the patient 
and local host reaction on the implant. Also, the examination of physical response of 




Figure 1.2 The old biomaterials paradigm [10] 
 
As the field developed, primary interest moved far from the search for inert (class 1: 
inert) materials to bioactive (class 2: interactive) materials. The materials were changed by the 
design of three-dimensional structures over two-dimensional interfaces and patient by cell, and a 
third factor, signal, was added. Each of these factors communicates with the other two: the cells 
are influenced by the matrix and signals; the signals are altered by cell action and a matrix while 
the materials can be influenced by cells and signaling molecules [11]. 
 
 




1.2.2 Types of Biomaterials  
 
Biomaterials must have specific chemical, mechanical, physical, and biological properties 
prior to their first performance as biomaterials inside the human body. Hence, implant materials 
should show favorable response in a given biological system which carries out extremely 
complex functions. For instance, the pH values in different tissues differ from 1 to 9. During 
daily activities, the force experienced by the ligaments and tendons is around 40– 80 MPa, while 
bones are subjected pressure roughly 4 MPa. Moreover, these stresses are repetitive and depend 
on the activities (jumping, standing, jogging). For example, for one year period the stress cycles 
occurred by the finger joint motion or hip joint motion are estimated to be as high as 1×106 
cycles while it is 0.5 ×107–4×107 cycles for a heart. This information roughly indicates the 
minimum and average numbers for biological environment where the biomaterials need to 
survive. Therefore, biomaterials are expected to be compatible with the biological systems. 
Hence, to meet certain standards, they are specifically developed neat or combined with classes 
of materials: polymers, metals, composite materials, and ceramics [12]. 
The classes of the materials are explained in the following sections:  
Polymers are suitable materials for biological applications, especially in the replacement 
of various soft tissues and implants, such as cardiac valves, artificial hearts, and dental materials 
[13]. Also, polymer materials have many advantages compared to other materials including 
simplicity and ease in manufacturing with convenient mechanical and physical properties, and 
suitable cost. The desired features of polymers can be obtained by adjusting the formation, 
structure, and organization of constituent molecules, [14]. Furthermore, the manufacturing of 
polymers with different arrangements and compositions is required for its adaptability for 
various applications to satisfy specific requirements. These manufactured for biological 
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applications polymers are defined as synthetic polymers. Although there are some approved 
synthetic polymers for biological applications, the inadequacy of biocompatibility in most cases 
is the disadvantage. Because of this, their usage in medical applications may result in 
inflammatory reactions. These disadvantages can be altered by using natural polymers (such as 
chitosan, carrageenan, and alginate) and bioactive materials as fillers inside the synthetic 
polymer to increase biocompatibility [15].  
Metals or metal alloys are the most preferred and demanded materials in the medical 
applications throughout history. The advantages of metals and metal alloys are their excellent 
biocompatibility, suitable mechanical properties, good corrosion resistance, and low cost [16]. In 
addition to this, their suitable tensile and fatigue strength make them perfect bearing materials 
compared to other classes of material such as polymers and ceramics. Furthermore, metals 
possess high toughness and elastic modulus but lower strains at failure compared to polymers. 
However, metals have relatively lower strength and higher toughness in comparison to ceramics. 
The choice of metals or metal alloys for the biomedical applications depends on the surrounding 
environment and its function. Their high tensile strength and fatigue limit make them good 
bearing materials compared to other classes of material such as polymers and ceramics. When 
the metal-based biomaterials are implanted into the body, the interactions between cells, tissues, 
and implanted material occur by the released by-products in consequence of changing and 
degrading of the surface of the biomaterial [14]. This factor enhances the understanding of the 
surface features of metal products to advance biocompatible materials. The stainless steel 
(316L), titanium and alloys (commercially pure Ti (Cp Ti), Ti6Al4V), cobalt chromium alloys 
(Co-Cr), aluminum alloys, zirconium niobium, and tungsten alloys are the most used metals as 
implants. The 316L type stainless steel (316L SS) is the most favored alloy in all implants from 
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cardiovascular to otorhinolaryngology applications. Co, Cr, and Mo alloys are preferred in need 
of high wear resistance for implant application such as artificial joints [10].  
Composites are the combination of at least two or more substances with different 
physical and chemical properties. They are designed to have superior and distinctive properties 
from the components. These materials obtain three phases; i) matrix (continuous bulk phase), ii) 
reinforcement (composed at least one discontinuous dispersed phase and has better properties 
than the matrix), and iii) interphase (phase between the matrix and reinforcing elements). 
Composites are implemented in some specific applications in which tissue ingrowth is required. 
Also, their excellent features make them alternative candidates for load-bearing tissue 
components. Further, composites can be tailored for calcified tissue applications such as skull 
reconstruction and bone, knee, and ankle fracture repair. For example, cancellous bone-like 
composite porous scaffolds combined with bioglass fragments were engineered, which have 
similar mechanical features to the cancellous bone [10].  
Ceramics are fundamentally inorganic, nonmetallic solids typically constituted at high 
temperatures. These materials are the specific class of biomaterials due to inertness in the body, 
high compressive strength, and excellent wear characteristics. The designed ceramic biomaterials 
for the biomedical applications are utilized in the musculoskeletal system, hip prostheses, 
artificial knees, bone grafts, and dental and orthopedic implants. Also, they are used as coatings 
on the surface of metallic implants to enhance their biocompatibility. Despite these criteria, their 
biomedical applications are less than metals and polymers because of their brittleness and low 
tensile strength. Hence, the phosphate bio ceramics are engineered and designed to overcome the 
brittleness and low tensile strength of the conventional ceramic biomaterials which have high 
biocompatibility and bone reconciliation, and also, they have a similar structure of the mineral 
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part of the bones [13]. The calcium phosphate-based biomaterials are utilized for various 
distinctive applications through the body, encompassing all territories of the skeleton. A couple 
of its applications are dental inserts, joint substitution, orthopedics, and treatments. Second, 
hydroxyapatite has been utilized as a filler in the bone imperfections and as implants in nasal 
septal bone [17]. It is also utilized as a coating on titanium, stainless steels, and metallic 
orthopedic and dental inserts to advance their affinity to the bone [18].  
1.2.2.1 Aromatic Thermosetting Copolyester (ATSP) 
 
Aromatic thermosetting copolyester (ATSP) is known as a cross-linkable aromatic 
polyester oligomer which was first produced by Frich et al. [19].  In the 1990’s, Prof. James 
Economy at University of Illinois at Urbana-Champaign advanced the ATSP research. The 
synthesis of the ATSP was done in two steps by controlling the molar ratios of the oligomers 
composed of biphenol diacetate (BPDA),4-acetoxy benzoic acid (ABA), isophthalic acid (IPA), 
and trimesic acid (TMA). In the reaction, carboxylic acid and acetoxy end group were 
incorporated by an endothermic condensation method. Biphenol diacetate (CB and CB2) was 
used in the carboxylic acid end group while acetoxy end group had biphenol diacetate (AB and 





Figure 1.4 Chemical structure of ATSP monomers and oligomer [20]  
 
The bulk aromatic thermosetting copolyester (ATSP) with the density of 1.27 g/cm3 for 
CBAB were produced by the following procedure: (i) blending ATSP oligomers (<90 um), (ii) 
curing the blend to produce foam, (iii) grinding the cured material to a powder, (iv) sintering of 
the cured powers via hot press. ATSP foams were produced by the same oligomer groups by 
entrapping acetic acid inside ATSP and the blowing agent (acetic acid) which formed a macro 
cellular porous structure inside the polymer matrix [20]. Also, the rigid rod structures have the 
poor solubility on any solvent; however, the branch structure of the ATSP enhances the 
solubility and allows ATSP to be produced into thin films. To obtain thin films, the solution 
ofcarboxyl and acetic acid end group oligomer in N-methyl-2-pyrrolidinone (NMP) was used 
and poured on the aluminum foil. During the curing process, no force nor vacuum were applied. 
The composed films were separated from aluminum by submerging the foil in concentrated 
hydrochloric acid (HCl) for seconds. The following steps involved washing the film with 
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deionized water and overnight drying process in the oven [21].  The composite ATSP polymers 
were produced by blending ATSP oligomers with 10% weight (wt.) hydroxyapatite (HA) and the 
same bulk, film and foam procedures were followed.  
ATSP has advantageous properties including low cost and ease in manufacturing. ATSP 
demonstrates excellent mechanical properties, especially in strength and stiffness. Besides, it 
demonstrates advantageous features as adhesives, matrices for composites, and coatings with low 
friction coefficient, excellent wear, and abrasion resistance. Their cross-link structures cause the 
inertness and stable properties. In addition to this, having robust adhesive features with metals, 
high energy absorption limit, and promising tribological properties make the ATSP a strong 
candidate for different orthopedic implant applications [20]. 
1.2.3 Characterization of Biomaterial  
 
A biomaterial should have essential qualities to be used efficiently as a material inside the body. 
These qualities are specified beneath.  
-    Nontoxicity: 
A biomaterial should be nontoxic inside the body and should not influence other organs and 
tissues. The toxicity can be defined as harmful leachable which segregates out of the material. 
Therefore, the nontoxic materials have no carcinogenic, pyrogenic, allergenic, and inflammatory 
responses [22].  
-    Biocompatibility: 
All biomaterials which are used in the body experience tissue reactions; therefore, 
biocompatibility is commonly characterized as the ability of a biomaterial to interact positively 
during a particular application. "Suitable host reaction" incorporates absence of blood clotting, 
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inflammatory response, and protection of bacterial colonization. Thus, the biomaterial is required 
to be biocompatible to work appropriately in patient's body [23]. 
-    An absence of Foreign Body Reaction: 
 
The responses created by the existence of a different substance in a human body are implied as a 
"foreign body reaction." This response will be different in intensity and period depending on the 
anatomical site. Therefore, biomaterials should execute all the criteria as proposed in the 
universal protocols and introduce no critical damage to the patient. The biomaterial should 
demonstrate no foreign body response [22]. 
1.2.4 Mechanical Properties and Performance of Biomaterials 
 
The coordinating of biomaterial physical properties with the vital organ/tissue properties 
is the most critical requirement. Biomaterials should have reasonable mechanical and 
performance features which are comparable to the supplanting organ/tissue. Subsequently, the 
materials should be designed considering the tissue environment where the devices will be 
utilized. The essential mechanical and physical requirements for the new biomaterial are 
mentioned under three titles specified below [23]: 
1.2.4.1 Mechanical performance  
 
One of the significant challenges in the biomaterial field is producing biomaterials with 
adequate mechanical properties. Mechanical performance of a biomaterial should show the 
proper and expected properties in the living body. The mechanical standards for the biomaterial 
fluctuate depending upon the site of utilization. For example, biomaterials, which are 
characterized by high mechanical stiffness and high strength, should be employed for 
applications where more mechanical support is needed such as hip joints. However, biomaterials 
that are preferred in the hip joint are entirely unacceptable for the use as artificial heart valves 
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which require biomaterials with more compliant elastic features than hip joint substitute 
materials. The mechanical performance of some biomaterials is represented in Table 1 [23]. 
1.2.4.2 Mechanical durability 
 
Durability shows the shortest time of duration of the material inside the body up to the 
longest duration time when a biomaterial adequately achieves its expected capacity. Clearly, a 
heart valve must be able to flex without tearing for a lifetime. The mechanical span of some of 
the biomaterials is specified in Table 1 [23]. 
1.2.4.3 Physical properties  
 
Biomaterials should have a particular physical property with a specific performance to 
achieve its desired behavior. Table 1 demonstrates the required physical properties for various 
biomedical applications [23]. 




1.2.5 History of Biomaterials  
 
The first synthetic biomaterials embedded into the human body were utilized many 
centuries ago. For example, a biomaterial was present in the remains of the human skeleton of a 
prehistoric Paleoamerican man found near Kennewick, WA (often referred to as the “Kennewick 
Man”). The spear point about 9000 years old was located in the hip of the body. Also,  scientists 
discovered gold wires which were utilized to link loose teeth in ancient Phoenicia. Furthermore, 
Mayan people used seashells to design nacre teeth in roughly 600 AD. The bone integrated iron 
dental implant was found in a corpse in 200 AD. In the early 20th century, bone plates were 
proposed to treat the fixation of long bone fractures. However, their mechanical design was not 
adequate for stress bearing because the structure was too thin, and stress was concentrating on 
corners. Instead, vanadium steel was chosen because of its good mechanical properties, but it 
caused both corrosion in the body and adverse effects on the healing processes. Therefore, better 
designs and materials were needed. The expected achievement was succeeded by stainless steels 
and cobalt-chromium alloy in terms of fracture fixation and the first joint replacement. Like 
metals, polymers, particularly poly (methyl methacrylate), were widely preferred for 
replacements of sections of damaged skull bones. With the further advancements in materials 
and surgical techniques, blood vessel replacements were tried in the1950s. During the 1960s 
heart valve replacements and cemented joint replacements came into usage. At the beginning of 
the twenty-first century, biomaterials were broadly employed in medicine, dentistry, and 
biotechnology [23].  
1.3 Biocompatibility 
 
The improvement in biocompatible materials began in the late 1960s with the 
acknowledgment that synthetic items could be adequately used as a part of the body. Although 
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these improvements in the biocompatible materials were beneficial, they also brought many new 
challenges with safety, quality, and the mechanical competence of biomaterials for the body. 
Because of these challenges, inquiries frequently emerged concerning security and the 
mechanical properties of the material, and how such qualities could be fulfilled preceding the 
devices utilized as a part of human patients. Particularly, the most difficult issues were the 
reactions of the human body against biomaterials and the response of tissues to these materials. 
This subject was given the name 'biocompatibility' [24].  
The term biocompatibility has encompassed the behavior of biomaterials in the living 
body. The thirteen most accepted definitions and terms of biocompatibility were decided by a 
consensus at the European Society for Biomaterials conference in 1986 [8].  In this conference, 
biomaterials were defined as “a material employed in a medical device which should interact 
with biological systems, while host response was described as the reaction of a living system to 
the presence of a material”.  The ability of a material to have an appropriate host response in a 
specific situation was assigned as the definition of biocompatibility [8]. 
Although those definitions are widely accepted, the most well-known meaning of 
biocompatibility was done by D. F. Williams (2008): “Biocompatibility is referred as the 
function of a biomaterial to be performed its desired capacity regarding a medical therapy, the 
most appropriate cellular or tissue response in that specific situation, and optimizing the 
clinically relevant performance of that therapy apart from revealing any defective local or 
systemic effects in the receiver of that therapy.” According to this definition, all biomaterials 
independent of their performing area should show a biocompatible reaction. More generally, 
biocompatibility can likewise be characterized as the connection between a material and the 
living being with the goal of producing no bothersome impacts [23]. 
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1.3.1 History of biocompatibility 
 
The examples of "biocompatibility" have been seen throughout history. The male body 
with a biocompatible spear point in pelvis dated 8000 years back was found in the territory of 
Washington (United States), close to the town of Kennewick. It is believed that this man 
survived with that lance point in his body during a long period of his life. One reason could be  
that the lance point was surrounded by a collagenous capsule (the foreign body response, FBR), 
and it was detached from person's body like a contemporary implant [25]. In 1931, the skull of a 
Mayan woman dated 600 AD was found with three seashell dentals during on archaeological 
excavation in Honduras [26]. Wrought iron was used as a dental implant for an upper tooth in 
France in the period of AD 100–200, as uncovered by a radiological examination. Additionally, 
the radiological image showed that osseointegration was comparable to the current criteria for 
the dental implants [27]. In the1890’s, the implant materials began to be used. German specialist 
Themistocles Glück utilized ivory and nickel-plated equipment to design a hip prosthesis. At the 
same period, a Czech specialist Vitezlav Chlumsky explored the possibility of utilizing of silver, 
magnesium, zinc, glass, plastic, and celluloid as hip joint interposition materials. British 
ophthalmologic specialist, Dr. Harold Ridley discovered that the pilots had unexpected 
implantations of windshield fragments in their eyes during World War II because of machine 
gunfire that broke airship windshield into small pieces. The windshield was produced from poly 
(methyl methacrylate) (PMMA) and Dr. Ridley realized that the fragments which were 
embedded into pilot’s eyes for few years had little inconvenience. Although Ridley never used 
the expression "biocompatibility," his perception of inertness and absence of negative response 
was long the present-day thoughts of biocompatibility. Subsequently, he used PMMA to make 
the first human intraocular lens (IOL), with the first implantation done in 1949 [28]. 
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The expression "biocompatibility" was developed around 1970, in a fundamental paper by C.A. 
Homsy, where the ideas of toxicology and its relationship to biocompatibility were elucidated 
[29]. In 1971, Homsy's thoughts were coordinated into a progression of tests to survey the 
appropriateness of materials for National Institutes of Health (NIH) [30]. 
1.3.2 Selection of biocompatibility analyses 
 
The approved and accepted biocompatibility assays are separated into three categories: 
essential (level I), secondary (level II), and preclinical (level III) tests. These groups include the 
cytotoxicity examination and irritating capability of entire systems in animals within muscular 
implants, skin implants, or in culture systems. Since the ATSP is a recently introduced material, 
in-vitro Level I tests will be the focus for the cytotoxicity tests of ATSP. In-vitro Level I assays 
evaluate the material properties in cultured cells environment to determine materials’ toxicity 
[31].  Since international standards and protocols provide documents which help in designing an 
appropriate test protocol, specialists should adhere to universal standards including Food and 
Drugs Organization (FDA) direction, ISO 10993: “Biological Evaluation of Medical Devices”, 
or The European standards EN 30993. Table 2 records the ISO principles for biocompatibility 
tests. The tests which are suggested for examining the biocompatibility or on the other hand 
biological impacts can be categorized as below [32]:  
            (A) Cytotoxicity or cell viability 
(B) Sensitization 
(C) Irritation 
(D) Acute systemic toxicity 







Table 1.2. The International Organization for Standardization (ISO) standards for 




Table 1.3. List of individual parts of ISO 10993 “Biological Evaluation of Medical Devices” [31] 
(parts with relevance to this study are highlighted) 
 
Cytotoxicity tests are the cellular level experiments that identify the toxic capability of a 
material or device [33]. These assays are sensitive, cheap, and the obtained outcomes are 
qualitative, quantitative, and practically comparable. The results permit the assessment of 
harmful materials prior to animal testing. Sensitization, also called allergic contact dermatitis, is 
a cutaneous reaction mediated by the immune response. It can be caused by periodic or 
continuous exposure to even a small amount of toxins. A sensitization response is shown as 
redness and swelling of the skin. Unfortunately, there is no settled in-vitro substitute assays [34]. 
In the Irritation test, the response is caused by chemicals discharged from devices or 
materials that contact the skin, eye, or mucous layer. Such irritation is defined as a local tissue 




The Acute Systemic Toxicity occurs because of the diffusion of chemicals from the 
material into the body where the substances may either positively or negatively affect organs or 
tissues within 24 hours after a dose [35]. 
The Subchronic Toxicity test is very similar to the Acute Systemic Toxicity test. The 
only difference is the testing time period which varies between 24 hours and 10% of the total life 
expectancy of the animal (for instance up to 90 days in rats) [35]. 
The Genotoxicity test examines the tendency of a medical device to prompt changes in 
the DNA structure of cells. There are three kinds of impacts, which should be tested 
independently: a) Gene changes, b) Changes in the chromosome structure, and c) DNA impacts. 
At least two of these tests should be performed in-vitro with mammalian or non-mammalian 
cells, microscopic organisms, yeast, or parasites [36] 
Implantation tests are essential to evaluate the local impacts of the implants on 
surrounding tissues [37]. Implantation can prompt constant irritation, with degeneration, and 
tumor development in the neighboring tissue [36]. 
The chemical leakage from a device can cause the undesired changes in the blood, such 
as a formation of hemolysis or thrombus. The Hemocompatibility test allows to check whether 
the device leads to changes in the blood [38]. 
The Chronic Toxicity test is fundamentally the same as the Acute Systemic and Sub 
Chronic Toxicity test, but the exposure time is higher than 10% of the life expectancy of the 
animal [35]. 
The Carcinogenicity test decides the tumorigenic capability of a device by presenting it to 
the animal throughout its lifetime. The Reproductive and Developmental Toxicity test assesses 
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the potential impact of the device on reproductive capacity, embryonic advancement, and pre-
birth and early postnatal improvement [36]. 
Biodegradation assays investigate the procedures of absorption, distribution, 
biotransformation, and disposal of leachable and degradation of items produced by the material 
segments of the device [39]. 
1.4 Test Programs and Descriptions  
 
The tissue environment where the material will be used and the residence time of material 
inside the body are primary criteria for selecting the reasonable test program. Hence, the 
requirements and the necessities for the different materials for different conditions will vary. For 
example, surface devices are intended to be in contact with skin temporarily for 24 hours, 
whereas an implant, which will stay longer than surface devices, has different necessities to be 
named biocompatible [40].  
Therapeutic devices can be categorized as Table 2, and the required and conducted tests 
for ATSP are labelled to accomplish a certification of biocompatibility. These essential 
experiments should be accepted as a guideline; however, each device is unique so some tests are 
not practical or extra tests, which are not demonstrated in the table, should be conducted. 
Therefore, the historical background of utilization of ATSP or reported assays of material for 
biocompatibility should be considered [40]. 
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Table 1.4. Biocompatibility matrix [40], parts with relevance to this study are highlighted. 
 
1.4.1 In-vitro cytotoxicity assays (ISO 10993-5:2009) 
 
 In-vitro cytotoxicity tests are well defined in ISO 10993-5 (ISO 10993- 5:2009) and are 
generally and regularly utilized for the assessment of biomaterials/medical equipment. The 
standard incorporates a timetable for testing which helps to decide the most proper assays for 
therapeutic devices [41]. Cytotoxicity tests have many advantages for toxicity assessment of 
therapeutic devices because they provide sensitive results and realistic estimate of toxicity and 
also decrease the number of animals used in cytotoxicity assays. The cytotoxicity test is one of 
the assessment and screening tests that utilizes tissue cells in-vitro to monitor the cell 
development, differentiation, and morphological impacts of medical equipment.  Three sorts of 
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cytotoxicity test are in the International Organization for Standardization 10993-5: Extract, direct 
contact, and indirect contact tests [42]. 
The direct contact test is fundamental for the materials/material parts that will 
individually confront the body cells. In this test setup, the surface structure and the chemical 
compound of the material or device may impact the cells. 
There are two potential applications for the direct contact test to analyze the material with 
cells: a) The cells are grown onto the material, or b) The cells are grown into a test vessel and the 
material is set over the cells [43]. 
An indirect contact test is designed to ensure that the surface properties are not affecting 
the outcomes. In this experiment, the cells and the material are isolated by an interface layer. The 
interface can be an agar-gel or a porous film. Hence, only dissolvable substances flowing out of 
the material can diffuse via the layer and cause cytotoxicity [43]. 
In the Agar Diffusion Test, materials which cannot react with agar can be used as a test 
material. Cells are seeded into the well plate, and culture medium layer with dissolved agar (0.5 
to 2% weight (wt.) is pipetted over them. After solidification, the sample can be set over the cell 
layer [28]. 
In the Extract Test, the extract of the material is added in different concentrations to the 
cell culture to assess its toxicity quality. The most common media are physiological saline, 
culture medium, dimethyl sulfoxide, polyethylene glycol, or vegetable oil. The extraction of a 
material is a complicated procedure influenced by parameters like the extent of the reaction, 





1.4.2 Cytotoxicity Evaluation Methods  
 
  The various characteristics and functions of the cell can be observed in the midst or after 
the cytotoxicity test [42, 43]. These properties can be classified into four different types of 
assessments:  a) Change in cell morphology, b) Cell growth (proliferation), c) Cell viability, and 
d) Enzyme action of cells.  
1.4.2.1 Cell Morphology 
 
To analyze cell morphology, either a light-optical and scanning electron microscopy or 
staining can be employed. The inspection of the cells should be done microscopically before the 
cytotoxicity test starts and before it is completed. Changes in morphology, differentiation, 
separation, or cell lysis should be recorded. The most customarily utilized methods are shown in 
Table 3, and the alamarBlue® and the MTT are clarified in more detail with regards to their 
utilization in this thesis [44]. 






1.4.2.2 Cell Proliferation 
 
The proliferation term is defined as a cell division which estimates the quantity of 
dividing cells in culture. The Colony Formation test is the least complicated technique to 
quantify the proliferation. A specific number of cells that are plated into an appropriate size flask 
is the first step for this assay. This step is followed by the counting of the number of colonies 
after the determined time points (after one day, two weeks or three months). However, this 
strategy is not easy for a significant number of samples [44].  Also, the markers like ³H-
Thymidine or 5-Bromodeoxyuridine (BrdU) can be fused into the DNA to gauge the DNA 
synthesis. These strategies give exact estimates. However, when many samples 
(immunohistochemistry) are required, the number of samples can create ambiguity in the results. 
The Detection of Antigens/Antibodies is a correct strategy when it comes to the observation of 
particular antigens or antibodies, which are present in proliferating cells [44]. 
1.4.2.3 Cell Viability 
 
The number of healthy cells can be used to define the cell viability. It is hard to distinguish if the 
cells are dividing or are inactive. Therefore, culturing and utilizing no dividing cells (primary 
cells) will be more favorable. Determining the number of alive cells can be done by counting 
them in the hemocytometer. Since this straight calculation has a risk of an error, it is not useful 
for a large number of samples. Therefore, indirect methods for counting the number of cells are 
preferred.  Some of the indirect cell counting for cell viability techniques are [44] as described 
next.  
 Radioactive chromium markers are fused into cells in the 51Cr Release test where the 
living cells hold this marker while the dead cells discharge the radionuclide into the medium. 
The scintillation counting is used to estimate the release and to distinguish the resultant light 
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pulse. This test has a few drawbacks including expenses, essential equipment, and safety 
prerequisites related to the treatment of radioactive materials [44]. 
The Trypan Blue Exclusion test is fast and simple to perform when analyzing the 
viability of cells. This assay depends on the absorption or exclusion of dye, which only dyes the 
dead cells because the non-harmful dye cannot saturate in the intact cell membranes. This test is 
regularly combined with counting cells in a Hemocytometer to recognize living and dead cells 
[44]. 
The Neutral Red Uptake technique allows to stain only viable cells as cells absorb the 
dye in their lysosomes. After washing the cells, subsequently they will extract the dye and the 
absorbance of the dye which is proportional to the viable cells measured by a spectrophotometer. 
The absorbance of the dyed cells can be estimated spectrophotometrically at around 550 nm [45]. 
The Crystal Violet Inclusion identifies the cell lysis. The dye only stains the living cells, which 
stick to the surface of cell culture flasks. At the point when cells experience lysis, they disengage 
from the surface. The living cells which absorbed the dye are distinguished 
spectrophotometrically. 
Lactate Dehydrogenase (LDH) is an enzyme existing in the cytoplasm of all cells. This 
enzyme is quickly flown out into the cell culture medium when the plasma membrane gets 
harmed. The LDH action can be efficiently estimated with samples obtained from the medium at 
a specific period. The enzymatic response involves two stages. First, discharged LDH are 
reduced NAD+ to NADH + H+ by oxidation of lactate to pyruvate. Second, the impetus 
(diaphorase) exchanges H/H+ from NADH + H+ to the yellow tetrazolium salt, which is a 
reduction of the yellow tetrazolium salt to red formazan. An increase in the amount of the LDH 
catalyst in the medium is due to a rise in the number of cells with a damaged membrane, and this 
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corresponds to the amount of formazan salt composed in a particular and constrained time frame. 
In this way, the quantity of dye generated in the test is proportional to the number of lysed cells. 
The formed formazan is a soluble dye in a culture medium and demonstrates absorption, most 
extreme near 550 nm [46]. 
1.4.2.4 Enzyme Activity 
 
3, (4,5-dimethyl-thiazol-2-Yl)-2, 5-diphenyltetrazolium bromide [MTT], the most 
broadly approved cytotoxicity test among other cytotoxicity assays, was introduced by Mossman 
in 1983. He utilized this semi-automated, colorimetric assay to quantify cytotoxicity, 
proliferation, and activation in lymphocytes [47]. The tetrazolium salt model presented by 
Mossman has been utilized broadly to recognize viable cells [49].  After Mossman published the 
paper, the article not only lead to broad utilization and approval of this assay but also helped to 
discover and solve non-disintegration of the formazan color. It also empowered the improvement 
of other scaled down, semi-automated, colorimetric tests like the LDH 96 well assay. Also, the 
test was tried on a broad scope of human cell lines, and in most cases, alive cell number were 
proportional to formazan generation [48]. Throughout the years, the MTT-based test is a 
standout amongst the other cytotoxicity assays in malignancy exams in cancer research for 
assessing cell viability, proliferation, and medication cytotoxicity. It can also be used for 
proliferation and cytotoxicity tests [49]. 
MTT [3, (4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyltetrazolium bromide], a water soluble 
yellow color solvent, is changed by the chemical succinate dehydrogenase in the mitochondria of 
metabolically active cells into a dark purple insoluble formazan item [47].  The enzyme 
reduction happens through its lipophilic side of cell membrane, and the positively net charged 
water soluble yellow solvent (MTT) can pass through the cell membrane. It is then reduced in 
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viable cells by mitochondrial or cell plasma proteins like oxidoreductases, dehydrogenases, 
oxidases, and peroxidases (Fig. 1.5). This reduction causes a transformation of a water-soluble 
tetrazolium salt to the water-insoluble formazan (dark purple color). The water insoluble purple 
formazan is able to be solubilized by dimethyl sulfoxide (DMSO), which is generally used to 
solve the formazan product [48]. The absorbance of dissolved formazan product is able to be 
measured between 570 and 590 nanometers (nm) via a plate reader [47]. 
 
 
Figure 1.5 Reduction process of MTT into formazon using enzyme reductase [50] 
 
The alamarBlue® Assay is the quantitative measurement of the proliferation of different 
human and animal cell lines. The assay is a colorimetric technique for the identification of the 
metabolic action of cells and is utilized to discover a relative cytotoxicity of different substance 
[51]. 
The technique depends on the reduction of resazurin (blue dye) and the fluorescent, 
colorimetric agent resorufin (pink dye) by metabolically active cells that allow diaphorase action 
[52]. This reduction results in change from non-fluorescent indigo blue to fluorescent pink state. 
The alamarBlue® reduction is examined by estimating either the fluorescence or the absorbance 
spectrophotometrically at two wavelengths 570 and 600 nm (Fig. 1.6). The fluorescent signal is 
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proportional to the number of live cells; thus, it allows an accurate quantification of changes in 
the rate of cell proliferation and day by day observation of the enzymatic movement of the cells 
[53].  
 
Figure 1.6 The absorbance wavelength of alamarBlue® [54] 
1.5 Experiment Setup for ATSP 
 
 As clarified at the beginning of section 2, biocompatibility is not only based on the effect 
of neighboring cells or tissue but also the expected functionality of the materials; therefore, a 
proper test setup should be performed by considering these two criteria. The assay should be 
simple, reproducible, and precise. Hence, the cytotoxicity assay was selected for this research 
since cytotoxicity tests are the initial step of the in-vitro biocompatibility analysis, and this test 
gives quantitative and similar results to the results of in-vivo assays. The tetrazolium-based MTT 
test was explicitly chosen for the cytotoxicity assay because it is accepted as the most sensitive 
and used as a high-throughput screening test. The principle of colorimetric MTT assay depends 
on the mitochondrial dehydrogenase action of viable cells. This test measures the metabolic cell 
activity by the result of an enzymatic transformation of the tetrazolium compound to water-
insoluble formazan by dehydrogenases, which happens in the mitochondria of living cells. In 
terms of cell line, human osteoblast cells were used in this experiment for cytotoxicity assays. 
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These cell lines are generally preferred and utilized for the initial step of cytotoxicity testing for 
bone implant materials. Also, they are easy to handle in culture and the results are accepted as 
proportional to in-vivo results. The MTT assay with human osteoblast and skeletal cell lines are 
the most suitable assays for ATSP because it is still in its improvement stage, and the neat and 
composite ATSP are not yet confined to a specific application or a body condition [55]. 
1.6 Materials and Methods 
1.6.1 Foam Samples 
 
The endothermic condensation polymerization reaction occurred between aromatic based 
acetoxy and carboxylic acid end-group oligomers. This reaction resulted in self-generated acetic 
acid that produced macro cellular porous morphology inside cross-linked ester backbone 
polymer lattice. ATSP foam samples were produced 6 mm in diameter and 4 mm in height with 
70% porosity (Fig. 1.7). Three different weights, 35 mg, 70 mg, and 105 mg, were measured by 
the precision balance in mg, and they were studied with the same amount of cell density to 
analyze the concentration effect on cell metabolic activity. The samples were sanded by 100- 240 
grit-sized sandpaper to reach the desired weight of 35 mg, 70 mg, and 105 mg. In addition to 
that, to produce the composite samples, the oligomers were mixed with 10% weight (wt.) HA 





Figure 1.7 Foam sample of ATSP 
 
1.6.2 Bulk samples 
 
Bulk samples of the ATSP were produced in four steps: (i) blending ATSP oligomers 
which was followed by (ii) curing the blend to create foam, and finally, (iii) the cured material 
was ground to a powder. At the next step, the cured powers were sintered through a hot press. 
The samples were cut into appropriate sizes 3 x 3 x 3 mm3 (Fig. 1.8) and bulk samples were 
again sanded by 100- 240 grit-sized sandpaper to get final weights of 35 mg, 70 mg, and 105 mg. 
Composite bulk samples were produced by adding 10% wt. HA to the oligomers and blending 
ATSP oligomers with HA, curing the blend to create foam, grinding the cured material to a 





Figure 1.8 Bulk Sample of neat ATSP 
 
Figure 1.9 Bulk Sample of composite ATSP 
1.6.3 Film sample 
 
The branched structure of ATSP enhances the solubility and allows ATSP to be produced 
as thin films. Film samples were created by pouring the solution carboxyl and acetic acid end 
group oligomer in N-methyl-2-pyrrolidinone (NMP) on the aluminum foil (Fig 1.10 and 1.11). 
For the composite films, 10% wt. HA was added to the oligomers in NMP, and the solution was 
poured onto the aluminum foil. During the curing process, no force or vacuum were applied to 
the neat and composite samples. Then, the neat or composite films which were deposited onto 
aluminum were separated from the aluminum foil by submerging it in concentrated hydrochloric 
acid (HCl) for seconds. The following step involved washing the film with deionized water and 
an overnight drying process in the oven [21]. The films were then cut and weighted as 35 mg, 70 




Figure 1.10 Film sample of neat ATSP 
 
 





1.7 Sterilization of Samples 
 
All of the samples were sterilized by overnight ultraviolet radiation (UV) to disinfect 
samples by destroying nucleic acids of microorganisms and harming their DNA, causing 
inactivation of cellular functions of organisms [56]. 
1.8 Characterization of samples 
1.8.1 Scanning Electron Microscopy 
 
Scanning Electron Microscopy images were taken with Hitachi S4700. The image  
belonging to a 6x4 mm2 foam sample is shown in Fig. 1.12.  
 
 
Figure 1.12 SEM image of foam ATSP sample 
 





Figure 1.13 SEM image of bulk ATSP sample 
 
The image belonging to a 5x5x5 mm3 film sample is shown in Fig. 1.14. 
 









1.8.2 Micro Computed Tomography 
 
Foam specimens prepared for micro-computed tomography (Micro-Ct) were 6 mm in 
diameter and 4 mm in height (Fig 1.15). The Micro-Ct scans of the porous samples were done by 
utilizing an Xradia MicroXCT-200 which allowed to image the internal structure of the 
specimens. After centering the test specimens on the stage of the instrument, scans of the 
samples were taken with a 2 seconds exposure time. The obtained 721 images were processed 
with Xradia MicroXCT Reconstructor software and the final images were seen by XM3DViewer 
(Fig 1.16). 
 





Figure 1.16 Micro-Ct Image of Foam ATSP sample 
 
1.8.2.1 Porosity Calculations of Foam Samples  
 
 Micro-Ct images were also utilized to measure the porosity of the foam samples. The 
average porosity value was calculated using five porous ATSP samples. For this calculation, 
intermode threshold method which changes the cross section to binary was applied to the images, 
and then solid area fraction was subtracted from each image. This subtraction equals the solid 
volume fraction which defines the porosity of samples. The black areas represent the pores while 
the white areas symbolize the bulk material (Fig 1.17) [57]. The porosity average of the five 
samples was 70% with 3.4 standard deviation.  
 
Figure 1.17 Example of Micro-Ct Image used in Porosity Calculation 
 
1.9 Statistical Analysis  
 
One-way analysis of variance (ANOVA) was performed on metabolic activity. 
Significance was set at p > 0.05. Analysis of metabolic activity included n = 3 samples per 
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group. The standard errors of the means were reported in the figures. There was no significant 
difference between groups and the results were consistent with each other.  
1.10 Methods 
1.10.1 Cell Culture Method Protocols 
 
The human osteoblast cell line (hFOB 1.19 (ATCC® CRL-11372™) was cultured in the 
Type 1 medium. The proportion of 1:1 blend of Ham's F12 Medium Dulbecco's Modified Eagle's 
Medium with 2.5 millimolar (mM) L-glutamine (without phenol red) was the base medium for 
this cell line. For complete media, the accompanying parts: 0.3 Milligrams(mg) /milliliters (mL) 
G418 and fetal bovine serum as 10% of final concentration were added to the base medium. 
 The human osteoblasts' cell line hFOB 1.19 (ATCC® CRL-11372™) was obtained from 
the American Type Culture Collection (ATCC® CRL-11372™) and used as a cell line to 
analyze the cytotoxicity of ATSP in this research. This cell line was gained by transfection of 
limb tissue acquired from an improvised miscarriage. For these analyses, the cells were 
developed in 75 cm2 cell culture (T-75) and placed in an incubator with 5 % CO2 at 37 °C. The 
cell culture medium was changed every two days to refresh nutrients and maintain the correct pH 
levels, and cells were analyzed every day under optical microscopy to assess changes in 
morphology or their attachment. 
1.10.2 The Protocol of Thawing, Culturing and Freezing Cell Line 
 
For cell thawing, the medium was warmed in a water bath at 37 °C to defrost the cells in 
the cryogenic vial. When the substance was dissolved, the cell suspension was moved into a 
15mL rotator tube, and the appropriate amount of culture medium was added and afterward 
centrifuged. The suspension obtained after centrifugation was expelled, and cells were 
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resuspended into a 25 cm2 cell culture flasks with 4mL culture media, and the flask was placed in 
the incubator. 
When the cells reached 80 % confluency after the incubation of the cell culture flasks, the 
subculturing of cells was required. The subculture of the cell lines was done by discarding the 
medium and washing the cells with 2-4mL Dulbecco's phosphate-buffered saline (DPBS) and 
then incubating them with a 2-4mL trypsin-ethylene diamine tetra acetic corrosive (trypsin-
EDTA) for 5 to 15 minutes at 37 °C. In the incubator, cells detached from the surface. The 
appropriate cell culture medium (either human skeletal muscle cell culture medium or human 
osteoblast cell culture medium) was added to neutralize the activity of the catalyst (trypsin). 
Cells were centrifuged in a 50mL tube for 3 minutes at 1000 rpm (150 x g) and resuspended into 
new cell culture flasks with 12mL culture media in a part proportion of 1:4. 
After resuspension, some number of cells were frozen in liquid nitrogen at below – 130 
°C to keep cells in stock and use them for further studies.  The cells were detached by 
trypsinization (as portrayed above) and re-suspended in cryogenic vials with solidifying blend 
which includes FBS containing 10 % (volume/volume) dimethyl sulfoxide (DMSO) as a 
cryoprotective operator. 
1.10.3 Protocol of MTT Assays 
 
5 mg MTT powder was added into 1mL autoclaved water to prepare the MTT reagent 
which was kept at 2 - 8° C in the dark. Since 1mL of solution and around 400,000 cells are 
required for 12 well plates, while 0.5mL solution and 200,000 cells at confluency are used for 24 
well plates use, six-well plates were used with the cell number 400,000 in each well [58]. Each 
condition was done in triplicate. Firstly, the flasks were trypsinized and the appropriate culture 
media, which is the double amount of trypsin (either human skeletal muscle cell media or human 
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osteoblast cell media according to the cell line used in the analysis), were added to trypsinized 
cells to neutralize the effect of trypsin. After that, the suspension which included trypsinized 
cells with neutralization media was centrifuged using a sterile centrifugation tube at 1000 rpm 
(150 x g) for 3 minutes.  Then, the media was removed and cells were resuspended with the 
appropriate media. The cells were then counted, and 400,000 cells were added into each six-well 
plate. Lastly, the plate was placed into an incubator overnight. 24 hours later, the media was 
removed and new media was added after washing with DPBS. Then, the cells were treated with 
neat and composite bulk, film and foam ATSP samples with the final volume 4mL. 44 hours 
later, 200 µL of 5 mg/mL MTT solution was added to each well including control wells which 
consisted of only the MTT solution but no material. Incubation of the well for 4 hours at 37 oC in 
culture hood was the next step of this process. After the incubation period, the media was 
removed carefully and 200 µL MTT solvent was added, and the absorbance at 570 nm was 
obtained after shaking for 1 minute (Fig. 1.18).  
 
  
Figure 1.18 The steps of the MTT assay 
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1.10.4 Method Setup 
 
The MTT samples and test controls were arranged in three replicates on four 6-well 
plates, according to the layout shown in Fig. 1.19. 
In the test 400,000 cells for each well were put in 4mL culture medium with the samples. 
The cells were first seeded and the materials were placed inside the well thereafter. Cells were 
watched day by day. The cytotoxicity test of ATSP samples were mainly categorized into two 
different groups: neat ATSP and Composite ATSP (ATSP+HA) and these two group had sub-
groups as bulk, film, and foam. These sub groups were tripled and done with 3 different 
concentrations of material (8mg/mL; 16mg/mL; 24 mg/mL) and were evaluated by the same 
number (400,000 cells) of osteoblasts cells (hFOB1.19). Cell viability was surveyed after 48, 
hours and assessed as portrayed in section 3.5.3. 
 
Figure1.19 Arrangements of the material samples inside the 6-well plate 
 
1.10.5 Calculations and Evaluation of Obtained Absorbance Values  
 
The absorbance readings from each well were put in the equation below to calculate the 
cell survival rate since MTT solvent reduction is accepted as proportional to the cell metabolic 
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activity. The absorbance readings were obtained by the reduction MTT solvent (yellow color 
solvent) to a dark purple insoluble formazan processed by the chemical succinate dehydrogenase 
in the mitochondria of metabolically active cells (Fig. 1.20).  
 
Figure1.20 The reduction of MTT to formazon 
 




∗ 100                                              [Equation 1] 
AMTT = Absorbance value of released MTT 
A = Absorbance of test well 
λ = 5700nm  
1.11 Results and Discussion 
 
The biocompatibility of neat and composite ATSP samples in the form of bulk, film, and 
foam were analyzed in-vitro by measuring mitochondrial dehydrogenase activity (MTT test) for 
48 hours and by the analysis of cell viability of human osteoblasts cells cultured in indirect 
contact with 3 different neat and composite ATSP forms. Also, three different concentrations 8 
mg/mL, 16 mg/mL, and 24 mg/mL for each form were tested. These concentrations were 
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obtained from changing the weight of the neat and composite ATSP samples (doubling and 
tripling the weight of ATSP) and keeping the number of cells the same to examine the effect of 
increasing concentration on human osteoblast cells. The effect of HA on the cell viability was 
analyzed by the composite materials. Experiments were done in a cell culture laboratory 
according to the requirements of ISO 10993 (biological evaluation of medical devices standard) 
to determine the cytotoxicity of the medical devices by quantitative methods (MTT). The results 
were obtained from MTT absorption and reflected mitochondrial activity in the viable cells. The 
percentage of cell viability higher than 90% was accepted as a good biocompatibility for the 
tested ATSP samples in different concentrations. The absorption for control cells was accepted 
as 100% viability. The rate of cytotoxicity was relied on the cell viability proportional to the 
control group. It was accepted that greater than 85% is non-cytotoxic, 60%– 85% is slightly 
cytotoxic, 30%– 59% is moderately cytotoxic, and less than 30% severely cytotoxic. 
 
 




Figure 1.22 Cell viability results of composite bulk samples by MTT 
 
 
In the metabolic cell activity results of neat and composite bulk samples with the MTT 
test by human osteoblast cells (Fig. 1.21 and Fig. 1.22), it is noticeable that neat and composite 
bulk ATSP samples did not demonstrate any toxicity for all concentration and all the values are 
higher than 90%. Furthermore, increase in the concentration did not change the results for all 
bulk samples (p>0.05). Composite bulk samples made of the mixture of HA and ATSP 
oligomers were used to investigate the HA effect over enhancing the metabolic cell activity. 
However, there was no increase in the cell activity with the presence of the HA (Fig. 1.22), and 
the results were similar to the neat bulk material (p>0.05).  Also, the result belonged to 8 mg/mL 
neat bulk sample was higher than 100%. When the results are over 100%, this could be a 
pipetting issue since the accuracy and precision of pipetting cells with the same density are 
important criteria in cytotoxicity assays. For each time, it is important to seed the same number 
of cells into the wells because seeding different cell density affects the results. When more cells 
pipet to a well, we can get a higher metabolic activity than others and sometimes the cell 
viability will be over 100%. To avoid inaccuracies in the results, the different steps of the plating 
cell should be considered such as pipetting the cells at vertical angle, gently mixing of the 
solution before pipetting, and using low immersion depth. Also, cells are experiencing shear 
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force during pipetting, and this force will negatively affect viable cells. Hence pipetting slowly 
and gently is another requirement.  
 
 
Figure 1.23 Cell viability results of neat film samples by MTT 
 
 
Figure 1.24 Cell viability results of composite film samples by MTT 
 
The lowest cell viability results, as compared to the control group, belonged to neat film 
samples, around 70% for each concentration (Fig. 1.23). Composite film results were around 
90%; these results had a satisfactory level of biocompatibility (Fig. 1.24). The low metabolic 
activity results for neat film could be due to either their adherence to the bottom of well plate or 
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tedious handling process. During the discarding process of the film samples, the cells could have 
been harmed because the cells were growing at bottom of the culture flasks. While taking the 
film samples out, it was possible to harm them with a physical stimulus.  On the other side, all 
the results for neat and composite film are consistent with each other. Both the increase in the 
concentration and the presence of HA did not change the results (p>0.05). 
 
 
Figure 1.25 Cell viability results of neat foam samples by MTT 
 
 
Figure 1.26 Cell viability results of composite foam samples by MTT 
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The neat and composite foam samples possessed the highest cell activity (Fig. 1.25 and 
Fig. 1.26). The results of foam samples were around or higher than 100%. The absorbance 
readings are based on the concentration of MTT, incubation time, the number of viable cells, and 
the metabolic activity of these cells. Even though the concentration of the MTT, incubation time, 
and the number of the viable cells were the same with others, there could be some abnormality in 
these criteria such as more cells than control group could be seeded in those wells. On the other 
hand, the structure and pore size of the ATSP could positively affect the results; also, the 
compound of the ATSP could be the reason for the high level of cellular activity. The presence 
of HA and different concentration treatment did not significantly affect the results, and the 
results were consistent with each other (p>0.05). 
It was mentioned in the Introduction that new biomaterials may show an adverse effect to 
the body, and thus they should be subjected to particular toxicity assays before their utilization in 
the body. In-vitro assays have been used to successfully to investigate the biocompatibility of a 
new material. The cytotoxicity assays are accepted as fundamental in-vitro assays to determine 
the potential toxicity of a new biomaterial. In-vitro assays for assessing the biocompatibility are 
able to distinguish the toxic material. They also provide the rapid estimation, standardized 
guidelines, and comparable data [59]. In this study, the biocompatibility of three different forms 
(bulk, film, and foam) of neat and composite ATSP were tested with the indirect contact test by 
MTT assay which analyzed extracts from each sample. These results showed that all of the 
analyzed samples except the neat film samples, did not show a cytotoxic effect and did not block 
cell proliferation, and thus have an acceptable level of biocompatibility. Also, the MTT assay 
revealed that none of the extracts from the tested samples affected the viability of the cells.  
However, as compared to the control group, the cell viability was around 70% for each 
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concentration of a neat film. Therefore, the neat film samples could be accepted as slightly 
cytotoxic. The reason for the low metabolic activity of neat films would be the higher surface 
area of film samples or the adherence of film samples to the bottom of the well plate that may 
have harmed the cells. Also, there were some results which have more than 100% cell viability. 
There is a possibility that the cells may have increased enzymatic activity without developing an 
effect on cell number or cell viability. Also, if the substance demonstrates no toxicity at a certain 
concentration, the viability can surpass 100%. There is another possibility that more cells than 
control group could be seeded in those wells due to small pipetting errors. However, if the 
metabolic activity percentage was far beyond 100%, it could mean the substance might also have 
an influence on the cells [60]. Furthermore, ATSP alone or in combination with other materials 
have a potential to be used in medical applications due to their inertness, tribological properties, 
high wear resistance, and excellent mechanical properties. Even though synthetic polymers do 
not have a functional group for stimulation of cell adhesion, they can bind bioactive particles like 
hydroxyapatite (HA) or protein sequences, which activate cell reactions [61].  HA was preferred 
as a filler in this experiment because HA has a similar chemical composition as the mineral 
component of bone, and it is well-known for its biocompatibility and osteoconductivity. Also, it 
is shown that HA-reinforced polymer composites increase biological properties [62]. However, 
the results showed that there is no positive effect of HA on the cell viability, the composite 
sample results were similar to neat results for each structure. 
1.12 Future Works 
 
Even though the neat and composite ATSP are promising candidates for therapeutic 
applications, the potential of ATSP for medical application has not been yet fully explored. 
Therefore, more in-vitro assays with different cell lines should be done in order to compare abd 
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determine if the results are consistent with each other. Currently, the MTT cytotoxicity assays 
using human skeletal muscle cells are being conducted for neat and composite film, bulk and 
foam ATSP samples.  Also, the long-term effectiveness of ATSP must be analyzed. In-vitro 
assays are the initial verifications of the in-vivo results, but the in-vitro results can cause 
misleading results while in-vivo studies provide conclusive results about new materials. 
















CHAPTER 2:  HUMAN MESENCHYMAL STEM CELLS DIFFERENTIATION 
REGULATED BY NEAT ATSP AND COMPOSITE ATSP (%10 HYDROXYAPATITE 
CONTENT WITHIN ATSP) 
2.1 Introduction 
 
Stem cells are particular cell types which can reestablish themselves through cell division 
and differentiate into multi-lineage cells. These cells are defined as embryonic cells (ESCs), 
induced pluripotent cells (iPSCs), and adult stem cells. Mesenchymal stem cells (MSCs) are a 
type of adult stem cells which can be obtained from human and animal sources. Human MSCs 
(hMSCs) are the non-hematopoietic, multipotent stem cells with the ability to differentiate into 
osteocytes, adipocytes, and chondrocytes [63]. 
Additionally, stem cells play a fundamental role in tissue regeneration in-vivo through 
lineage differentiation caused by environmental components. Previously, biochemical signs were 
the main point of induced stem cell differentiation. As revealed by Engler et al. 2006 [64], stem 
cells differentiation is intervened by biophysical signals, which could likewise perform as a 
critical inducer. Hence, producing dynamic biophysical signals to coordinate stem cell fate 
through uniquely composed material microstructures has become important. These outlined 
biophysical signals incorporate the material elasticity/rigidity characteristics, micro patterned 
structure, and porous structure. Many examinations have been done on material coordinated 
mesenchymal, embryonic, adipose stem cell, and differentiation [65]. 
Recent studies have indicated that substrate signals significantly influence the growth and 
differentiation of mesenchymal stem cells (MSCs), and that in-vitro and in-vivo differentiation 
of MSCs along the osteogenic pathway appears to be highly dependent on the substrate 
composition. For the use of hMSCs in bone regeneration, it is particularly important to 
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understand the interactions between hMSCs and materials because cell–material interactions play 
an essential role in the bonding of implant materials to native bone tissue. [66] 
Natural materials demonstrate excellent potential as an implant material as a result of 
their convenience and innate biocompatibility, while synthetic materials have an advantage that 
they can be engineered to have different properties. A few cases of engineered materials are 
polylactic corrosive (PLA), polycaprolactone (PCL), and poly(lactide-co-glycolide) (PLGA) and 
𝛽 tricalcium phosphate (𝛽 TCP) [67]. 
Mesenchymal stem cells (MSCs) are the most broadly studied cell lines in biomedical 
applications. These cells differentiate along the osteogenic lineage when seeded on various 
substrates including hydroxyapatite containing frameworks and can be utilized as a remedial 
choice to recover different tissues [66]. Hydroxyapatite (HA) has conclusively affirmed its 
osteoinductive properties in-vitro and in-vivo [68]. 
Since the cell viability assays with MTT by human osteoblast cell line showed that the 
ATSP forms did not have a significant cytotoxic effect (Chapter 1) and the foam had the highest 
cellular activity results, the direct contact interaction between hMSCs and the ATSP foam 
directly was investigated in this chapter. Our goal was to characterize the response of human 
mesenchymal stem cells (hMSCs) to a novel porous neat and composite materials for bone tissue 
engineering applications. The morphology of the porous neat ATSP and composite was 
investigated by scanning electron microscopy (SEM). The hMSCs cell proliferation and 





2.2.1 Foam Samples 
 
The foam structure is produced by self-generated blowing agent (acetic acid) caused by 
the endothermic condensation which was generated between aromatic based acetoxy and 
carboxylic acid oligomers. Two different type of foam samples including neat ATSP (scaffold) 
and ATSP with 10% HA (composite) were produced 6 mm in diameter and 4 mm in height with 
70% porosity. Two different samples were tested in both regular growth media and osteogenic 
media. The design of the assay was categorized as scaffolds with growth media, scaffold with 
osteogenic media, composite with osteogenic media, and composite with growth media.  
2.3. Cell Culture, Assay, and Imaging Protocols  
 
In this chapter, the human mesenchymal cell line (hMSCs) (Lonza PT-2501) was used. 
These cells lines were disconnected from ordinary (non-diabetic) adult human bone marrow 
pulled back from bilateral punctures of the posterior iliac crests of typical volunteers. Cells were 
cultured in two different media (complete growth media and osteogenic media) and put in a 
humidified atmosphere containing 5% CO2 at 37ºC.The new media was added twice per week to 
maintain the pH of the environment and adequate nutrients for cells. The passage five cell lines 
were used for all experiments.  
2.3.1. hMSC culture and differentiation protocol  
 
Both protocols, normal growth media and osteogenic media, were performed in the 
laminar flow hood [69]. The reagents of the completed normal growth media for the human 
mesenchymal cell line (hMSCs) were 445mL low glucose DMEM (Fisher SH30022.FS), 50mL 
MSC-validated fetal bovine serum (Invitrogen 12662-029), and 5mL antibiotic-antimyotic 
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(Invitrogen 15140-122). The osteogenic media was also prepared in the same way with the 
normal growth media protocol but additionally 0.1 micro molar (µM) dexamethasone (Sigma 
D4902-100MG); 10 mM beta-glycerophosphate (Sigma G9422-10G); 50 micro molar (µM) 
ascorbic acid (Sigma A4403-100MG) were added. After the completion of both media, 
sterilization was done by a filter before use [69]. 
2.3.2. MSC thawing and counting procedure  
 
Before thawing a frozen cell vial, the complete MSC medium was placed in a water bath 
and warmed to 37oC. The frozen cell vials were put in water bath for 2 minutes in 37oC. Then, 
the thawed cells and freezing medium were transferred to a 15mL centrifuge tube. The complete 
MSC medium was added, and the volume was brought up to 9mL. The 10mL cell suspension 
was removed for counting. The 15mL centrifugation tube was placed in the centrifuge at 600 g 
for five minutes. After the cells were spun, they were seeded at the required density (usually 
5,000-6,000 cells/cm2).  The media was used according to the flasks’ size; around 10-12 mL for 
a 100-mm dish, 12-14 mL for a T75, or 7-8 mL for a T25. The flask(s) were placed into the 
incubator. The confluence was checked every 24 h, and the media of cells were changed twice a 
week [69]. 
While cells were spinning down, the 10 µL cell suspension for counting were mixed with 
10mL of Trypan blue, and the mixture was pipetted several times to mix the stain and cell 
suspension. Then, 10mL of the stain/cell suspension was pipetted into the hemocytometer to 
count the number of alive cells. The average number of cells per area was utilized to measure the 
cell population. For this count, the dilation element was accepted as 2 (1:1 ratio of cell 





TCP = (MCR) * D* 10,000 * (CSV)                                            Equation 2  [69]   
TCP = Total Cell Population 
MCR = Mean Cells per Region 
D = Dilution 
CSV = Cell Suspension Volume 
 2.3.3. MSC passaging procedure  
 
The complete MSC media, sterile PBS, and 3mL trypsin-EDTA were warmed in a water 
bath to 37oC. All of the media from each T75 flask were removed, and 10mL of PBS was added 
to per T75 waited for 30 seconds. The PBS was removed and 3mL of trypsin was added per T75 
flask. Then, the flasks were returned to the incubator for 8 minutes to allow for the cells to 
detach from the flasks. 6mL of complete MSC media was added to each flask to neutralize the 
trypsin. The suspension, made up of the trypsin, additional media, and cells, was put into a 
conical tube. The 10mL cell suspension was removed for counting. Then, a tapered tube was 
centrifuged at 600 g for 5 minutes. The media supernatant was aspirated, and new media was 
added to dilute cells to the desired concentration. The cells were seeded according to the 
requirement [69]. The cell counting was done as explained under the MSC thawing and counting 
procedure section. 
2.3.4. MSC freezing procedure 
 
For MSC freezing procedure, the MSC passaging procedure was followed until aspirating 
the media and resuspending.  After this, the volume of freezing media that is required to 
resuspend 1-10 x 106 cells per mL was added to cryopreservation vial. The reagents of the 
53 
 
freezing media were 50% complete MSC media, 40% FBS, 10% DMSO. 1mL cryogenic tubes 
were filled with cells and freezing media in the ratio of 1:1. Cryogenic tubes were placed in a -
80oC freezer [69]. 
2.4. Quantification of MSC metabolic activity 
 
hMSCs cells were cultured until they reached 80% confluency before preparing the plates 
for the cytotoxicity assay. Cells were seeded on the dry scaffold at a density of 7.7 x 104 cells per 
well in 24-well-plates (Fig. 2.1). Every row of the plates was treated with normal growth and 
osteogenic media, and the experiments were performed in triplicate. The readings of the cell 
viability using the alamarBlue® assay were performed for one day, four days, and seven days.  
 
Figure 2.1. The schematic of alamarBlue® Plate 
The metabolic activity of MSCs in scaffolds and composites were assessed using the 
alamarBlue® assay (Invitrogen). AlamarBlue® quantifies the mitochondrial metabolic activity 
by the continuous reduction of the alamarBlue® dye (resazurin) to the fluorescent byproduct 
resorufin by healthy, active cells. Fluorescence was measured (excitation: 540 nm, emission: 600 
nm) on a fluorescent spectrophotometer [69]. 
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2.4.1. Ethylene Oxide Sterilization of Scaffold 
 
The foam samples were sterilized by exposure of the sample to the ethylene oxide, which 
is a sterilization method of a medical device or component.  
The EO high reactivity, as communicated by the high energy of its exergonic ignition 
response, in combination with its high diffusivity, is of real significance for the inactivation of 
microorganisms. The consequence of its effective alkylation response with cell constituents of 
organisms are thought that there is no need for metabolic activation, and its inactivation 
properties are, for example, nucleic acid and proteins, including compounds, which result in 
denaturation [70]. 
The EO sterilization method was actualized according to ANSI/AAMI/ISO 10993-7: 
2008, which defines acceptable limits for residual ethylene oxide (EO) in an individual EO-
sterilized medical device. The lethality of EO sterilization relies upon the accompanying four 
process parameters: (i) the concentration of EO, (ii) exposure time, (iii) temperature, and (iv) 
humidity. The concentration of EO for sterilization was 100% EO at low temperature (30– 
60oC). As described in the protocol, the samples were placed into gas-penetrable packs and put 
in the sterilizer for three hours. Overnight air circulation in the encompassing environment was 
then performed [70]. 
2.4.2. Scaffold hydration 
 
All plates were labeled according to the combinations of different samples and different 
media as shown. A total of 72 samples were used, and they were placed into six-well plates as 
each well had six scaffolds. The samples were set according to the type, and 4mL of appropriate 





Figure 2.2 from left to right; composite (ATSP+HA) with osteogenic growth media (COM), 
composite (ATSP+HA) with regular growth media (CGM), scaffold (neat ATSP) with 
osteogenic media (SOM), scaffold (neat ATSP) with regular growth media (SGM) 
2.4.3. Standard curve for alamarBlue®   
Before beginning the assay, a standard curve was created with a known number of cells. 
The standard had eight sample points. These points included a well with just media, a well with 
media and alamarBlue®, and 24 wells with media, alamarBlue®, and an alternate number of 
cells. An illustration standard setup was as shown in Fig 2.3:  
 





The well containing all media was a negative control while the background control was 
obtained from a control-well, and other wells were utilized to make the standard curve. The 
diluted cell number calculations were calculated as below: 




The standard curve plate was placed on the shaker (~50 rpm) in the incubated at 37oC for 
4 hours. During this process, the viable cells changed inflorescent resazurin to the fluorescent 
resorufin. After this process, a curve of known cell number and absorbance was obtained, and the 




Figure 2.4 The alamarBlue® reduction into standard plate 
After incubation, 100 µL were taken from each example and placed into a 96-well plate 
to make three replications. The fluorescence (excitation: 540 nm, reference: 600 nm) on the 
spectrophotometer were measured by using 'AlamarBlue® F200' program. The average of each 
data points was calculated to draw the standard curve; the change of the fluorescence reading 
was calculated by subtracting the results from well 2 (control well) as shown the formula below. 





Table 2.2. The calculations of percentage reduction of alamarBlue® 
 
2.4.4. Seeding cell on the scaffold 
Six samples with 6 mm in diameter and four (4) mm in thickness for each group were 
used. 20µl total cells (so 10µl each side) were seeded on the scaffold and then we waited 30 
minutes on each side (hour in total) before adding 1mL of media. The samples were placed 
according to their group; (i) scaffold (neat ATSP) with growth media, (ii) scaffold with 
osteogenic media, (iii) composite (ATSP+HA) with growth media, and (iv) composite with 
osteogenic media were put into wells of 24-well tissue culture plate. Then, the samples were 
placed into the incubator at 37°C and 5% CO2.  
2.4.5. alamarBlue® Protocol 
At each chosen time point after seeding the cells (i.e., 24, 96, and 168 hours) the samples 
were taken out of the incubator, washed in PBS, and then placed each in a 24 well plate with 100 
µl alamarBlue® and 900µl media, with one of the wells being a control again. The plate was put 
in the incubator on a shaker for the same period as the standard plate, and then the foam 
materials were removed and placed them in their original wells. A short time later 50 µL were 
59 
 
taken from each well and suspended into a 96-well plate in triplicate and we read the absorbance 
of the plate. The absorbance was estimated spectrophotometrically at 570 nm and 600 nm. We 
then used the same protocols on day 4 and day 7, doing the same procedure [69]. 
2.5. RT PCR 
The qualitative assays are the most widely recognized protocols for analyzing in-vitro 
osteogenesis. These assays are dependent on dyeing insolvable parts of the discharged ECM, 
such as calcium, phosphate, and collagen. In addition to this technique, the colorimetric process 
of labeling molecules (reporter) by alkaline phosphatases (ALP) was utilized to investigate 
osteogenesis. These tests had restrictions in that they depended vigorously on microscopic 
visualization of the dying and objectivity of the specialist. Therefore, quantitative RT-PCR and 
microarray examinations are preferred assays among others for estimating osteogenesis, because 
these techniques are delicate and more quantifiable [71]. 
Real-time PCR (or qPCR) is a broadly utilized gold standard for quantitative 
investigation of gene expression. The recognition of intensification of DNA in real time as PCR 
is detected by the utilization of fluorescent reporter, which is the crucial component of the PCR. 
The fluorescent reporter signal intensity is relative to the number of amplified DNA molecules.  
Between 2001 and 2010, RT-PCR has been utilized as a ground-breaking assay for genotyping 
(Alker, 2004) [72], measuring viral load, and gene copy number tests. RT-PCR is the highest 
quality level of gene expression level test [71]. 
There are two ascertainment strategies for RT-PCR. The first strategy, which is called the 
TaqMan test, depends on a particular probe sequence. The TaqMan analysis is a generally 
utilized RT-PCR assay because of its affectability and specificity. DNA polymerase 5′– 3′ 
exonuclease activity form the basis of the TaqMan assay. Figure 2.5 shows the schematic of 
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TaqMan test protocol. The TaqMan test is a sequence-specific oligonucleotide with a 
correspondent fluorescent color at 5′ end and a quencher color at 3′ end. When there is no probe 
hydrolysis by TaqMan DNA polymerase process, a quencher fluorescent stain will absorb the 
reporter stain’s emitted fluorescent light. However, when Taq DNA polymerase hydrolyzes the 
probe, the 5′ reporter fluorescence stain is isolated from quencher stain. Hence, the quenching 
effect will be lost and the discharged 5′ reporter fluorescent stain signal can be measured by the 
RT-PCR instrument [72]. 
  
 
Figure 2.5 The schematic of TaqMan test protocol [72] 




The extraction and quantification of total RNA is the first step to obtain the appropriate 
amount of RNA, which is used to implement first-strand cDNA synthesis through reverse 
transcription. Typically, greater than 10 ng of cDNA is preferred per well for real-time RT-PCR 
experiment.  
RNA was extracted from MSC-seeded platforms at time-frames one, four, and seven 
days, employing a RNeasy Plant Mini kit (Qiagen, Valencia, CA) [69] and transcripted to cDNA 
with the QuantiTect Reverse Transcription pack (Qiagen). PCR responses were performed in 
triplicate utilizing TaqMan on an Applied Biosystems 7900HT Fast Real-Time PCR framework. 
Since Mesenchymal Stem Cells (MSCs), which are viewed as crucial cell elements for the usage 
of cell-based ideas in the field of regenerative medication, have been effectively used to 
regenerate wounded bone, ligament, cardiovascular tissue, and other types of tissues. Specific 
transcription factors and signaling pathways manage the osteogenic differentiation of MSCs. The 
osteopontin (SPP1), bone sialoprotein 2 (IBSP), runt-related translation factor 2 (RUNX2), and 
GAPDH were used for gene expression in this research. Runt-related translation factor 2 (Runx-
2) is accepted as an early osteogenic differentiation marker. Decrease in the expression of Runx-
2 results is insufficient bone formation since this translation factor is viewed as a main controller 
of osteogenesis. Runx-2 influences other bone-particular genes, bone sialoprotein 2 (IBSP), by 
attaching to particular promoter districts. The expression of IBSP are mostly seen in mineralized 
tissue as it stimulates mineral formation in the bone. The high-level expression of IBSP means 
the mineral and nodule formation occurs in the material or increase in the osteoblast related gene 
expression are seen [73]. Runx-2 is known as a crucial factor for osteogenic differentiation and 
also it plays a fundamental role in formation of mineralized tissue. Osteopontin (SPP1) is used as 
an early osteogenic marker. SPP1 is a protein found in bone matrix, which regulates the 
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biomineralization. The presence of the SSP1 expression in the results suggests that this material 
can act as a structural substance [74]. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was used as a housekeeping gene, which is one of the most commonly used housekeeping genes 
in comparisons of gene expression data. Data were examined by the Comparative CT Method 
(ΔΔ CT Method), which is used to evaluate a lot of samples results. The Comparative CT 
Method utilizes an arithmetic formula to accomplish the outcome for the relative quantitation 
[72]. 
Step 1-RNA isolation 
 
The platform was washed out with PBS, and afterward, RNA was removed from 
scaffolds through an RNeasy Plant Mini (Qiagen 74904) kit, as beforehand depicted at Duffy, 
McFadden, et al. 2011 [75]. The RNA isolation protocol is explained as follows: 500 µL of RLT 
lysis buffer supplemented with β-mercaptoethanol was added to each tube and was kept on ice 
for ~ 5 min. The cells were shaken regularly to assist cushion to infiltrate through the scaffolds. 
The appropriate amount of lysis buffer was measured, and it was pipetted into a labeled 
QIAShredder column with the scaffold. The tubes were spun at 14,000 rpm for 2.5 minutes. 500 
µL of 70% ethanol was added to each sample [69]. 
Half of the lysate + ethanol solution was added to the labeled RNeasy column (with a 
2mL collection tube), and it was spun at 12,000 rpm for 30 seconds. After that, the remaining 
liquid was discarded, and the column was replaced. The remaining lysate + ethanol solution was 
added to the column and centrifuged at 12,000 rpm for 30 seconds. Again, the obtained 
suspension was discarded, and the column was replaced. 700 µL Buffer RW1 was added to the 
column which was centrifuged at 12,000 rpm for 30 seconds. The same procedures, discarding 
flow and returning the column processes, were repeated. After this, 500 µL Buffer RPE was 
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pipetted into the column, and again it was centrifuged at 12,000 rpm for 30 seconds. Before 
adding another 500 µL Buffer RPE into the column and centrifuging at 12,000 rpm for 2.5 
minutes, the obtained flow and the column were eliminated. The following step included 
discarding the fluid, replacing the column with a new 2mL collection tube, centrifuging at 
12,000 rpm for 2 minutes, and transferring the column to a new 1.5mL collection tube. The final 
step was pipetting 30 µL RNase-free water into the column and waiting five (5) min before 
centrifuging the RNeasy column at 12,000 rpm for 1.5 minutes. After the final step, the RNA 
was stored at -80°C for later use or put on ice directly proceeding to quantification, reverse 
transcription, and RT-PCR [69]. 
Step 2- Quantification of RNA 
2 µL RNA free water was used as a control to set up the NanoDrop Lite (Fig. 2.6) which 
is utilized for micro volume measurements of nucleic acid concentration at 260 nm, using the 
260/280 ratio and purified protein concentration at 280 nm. The quantifying of RNA was 
performed by the NanoDrop Lite using 2 µL from each sample. The platform was cleaned with a 
Kimwipe wipers between each sample. The readings were done spectrophotometry and recorded 





Figure 2.6 NanoDrop Lite 
The calculation of RNA amount was done as microgram (µg) utilizing the following equation; 
 Equation 3 [69] 
 Equation 3 [69] 
 
Step 3-Generate cDNA with Reverse Transcriptase 
The RNA reverse transcription to cDNA was performed by the QuantiTect Reverse 
Transcription kit in a Bio-Rad S1000 thermal cycler. PCR tubes were labeled according to the 
number of reactions needed. The QuantiTect Reverse Transcription kit components and RNA 
samples were put on ice, while a thermocycler was turned on to warm up at 42° C. 200 µL 
conical tubes were labeled with sample identifiers as one per sample. The volume of RNA 
sample demanded a 10 µL reaction (generally 10 ng of cDNA will be desired per well for the 
real-time RT-PCR experiment) were calculated as the following equation which includes 1.10 is 




After the RNA volume was calculated, the amount of water required for each reaction was 
calculated so that the total volume of RNA and the water equaled to 6uL. If the total quantity of 
total RNA is more than 6 µL, there is no requirement for adding water since 6 µL of RNA is 
enough to fulfill the requirement. After calculation, the lack amount of RNA was completed with 
the demanded amount of water into each 200 µL conical tube. Then, one µL of gDNA wipeout 
was added to each tube, which was mixed with either a pipette or vortex. The required RNA 
volumes were pipetted into each tube, and the tubes were fused by pipetting and placing into 
thermocycler to incubate at 42°C for 2 minutes. ‘CAV1’ program was run, and the volume was 
changed to 10 µL. While incubating, 2.5 µL of RT buffer/primer mix was combined with 0.5 µL 
reverse transcriptase per sample into a tube. After the incubation was completed, 3 µL of reaction 
buffer mix were put into each PCR tubes and placed back to the incubator for 15 min at 42°C, 
which was followed by 95°C incubation for 3 minutes. When the incubation time was over, the 
samples were removed at -20°C [69]. 
Step 4- qPCR – TaqMman 
First, the volume of reaction mixture was calculated. The calculation was made as a ten 
µL reaction volume per well. TaqMan Fast Advanced Master Mix (5 µL) constituted the half of 
the reaction volume. The other half of the amount was composed of 0.5 µL TaqMan Gene 
Expression Assay per well and the mixture of RNase-free water and cDNA. The calculation of 
the mixture volume of RNase-free water and cDNA per well was made as follows: 
  
RVW – MMV – TGEAV = VRfW                                     Equation 4 [76] 
RVW = Reaction Volume per Well 
MMV = Master Mix Volume 
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TGEAV= TaqMan Gene Expression Assay Volume 
VRfW= Volume of RNase-free water and cDNA 
                                                    
Then, the master mix, which consisted of TaqMan Fast Advanced Master Mix and Gene 
Expression Assay for each gene, was prepared. The total volume of the master mix was 
calculated in the following way: 
 
1.10 (x) *NS * NR* (VTMM + VTGEA) = VMM                                   Equation 5 [76] 
X = excess solution 
NS = Number of samples 
NR = Number of replicates/sample 
VTMM = Volume of TaqMan Master Mix/reaction 
VTGEA = Volume of TaqMan Gene Expression Assay/reaction 
VMM = Volume of Master Mix 
  
The cDNA and add RNAse-free water solution was thawed, and the total volume of the 
solution was calculated according to the following equation:  
  
1.10*NS * NR* VRfW = TVRfW                                                            Equation 6 [76] 
NS= Number of samples 
NR= Number of replicates/sample 
VRfW= Volume of RNase-free water and cDNA/reaction 




The master mix was added to the plate and the RNase-free water and cDNA followed it. 
The plate was sealed with a transparent adhesive before centrifugation. QuantStudio 7 Flex Real-
Time PCR System was used to analyze the plate.  Results were evaluated utilizing Sequence 
Detection Systems programming v2.4 (Applied Biosystems) according to the delta-delta Ct 
strategy. GAPDH was used as the housekeeping gene, and effects were introduced in respect to 
the GAPDH [76]. 
Calculations: 






2.6. Statistical analysis  
One-way analysis of variance (ANOVA) was performed on metabolic activity and gene 
expressions. Significance was set at p < 0.05. Analysis of metabolic activity included n = 3 
samples per group while gene expressions used n = 5 samples per group. The standard errors of 
the means were reported in the figures. There were significant differences between groups and 
days. 
2.7. Results and Discussion 
 
A synthetic bone substitute requires a porous matrix, which has an interconnecting 
porosity that increases rapid bone growth. Also, it should have adequate strength to preserve its 
mechanical properties under physical loads. It should also form a secure framework that allows 
and stimulates growth and penetration of new cells into pores. One possibility to meet these 
requirements is to utilize porous materials that allow new bone and tissue formation by 
permitting the cells growth into pores because the large surface area of pores permits cell 
attachment, growth, and differentiation [77]. Biomaterials with mineral content have a significant 
role in tissue engineering; they are accepted as osteoconductive biomaterials and generate a 
potential biological bone substitute [78]. The need of porous materials which not only allow new 
bone formation but also are able to blend with mineral is crucial for bone substitute materials.  
Therefore, neat and composite (10HA%+ATSP oligomers) porous samples of ATSP were 
fabricated. Both neat and composite foam samples were seeded with MSCs and cultured for one, 
four, and seven days. The foam samples were cultured in growth and osteogenic media. The 
groups were categorized as: (i) scaffold(neat samples) with growth media (SGM), (ii) composite 
with growth media (CGM), (iii) scaffold with osteogenic media (SOM), and (iv) composite with 
osteogenic media (COM). During the culture period, the mitochondrial metabolic activity of 
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MSCs on the samples was measured by using an alamarBlue®absorbance assay. Samples were 
seeded with MSC and incubated in alamarBlue® solution for 2.5 hours. AlamarBlue® dye was 
reduced by viable cells to a fluorescent byproduct (resorufin). Absorbance values were used to 
calculate the reduction of alamarBlue®  (excitation: 570 nm, emission: 600 nm). The reduction 
of alamarBlue® was calculated according to the equation provided by the manufacturer (Table 
13) and the experiments were performed in triplicate [79]. 
 
Figure 2.7 The metabolic activity of foam samples with alamar blue by MSCs 
 
MSC metabolic activity was performed by alamarBlue® (Figure 2.7). Through the 
experiment, the results were compared to the red line which corresponds to 1 (threshold). This 
value (1) was accepted as the metabolic cell activity of the cells which were initially seeded on 
the samples. The highest metabolic activities were found in SGM and COM in day one, and none 
of the samples showed a toxic effect; the results for all samples were higher than initial 
metabolic activity values (greater than one). The samples did not cause cell death and allowed 
the cell proliferation. Statistical analysis also showed a significant effect of both the culture time 
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and scaffold type (p < 0.05). All of the results on day four were less than the results of the first 
day. However, they were still higher than or at least equal to the threshold value (greater than or 
equal to one). For day seven, the pattern belonged to CGM, SOM, and COM were analogous to 
other days’ patterns; however, the result for SGM was different. CGM, SOM, and COM were 
initially behind the SGM, but they eventually approached and even surpassed the metabolic 
activity of the SGM at day seven (p < 0.05). The results showed that mineralized samples had a 
positive effect on the metabolic activity because the composite samples showed high metabolic 
activity in comparison to neat samples on day seven (p < 0.05). Also, osteogenic groups (SOM 
and COM) demonstrated the highest metabolic activity compared to the other groups on day 
seven. The metabolic activity of all the samples on day seven was significantly higher than the 
threshold level (p < 0.05). Therefore, it could be said that our samples were allowing cell 
proliferating and growth. Moreover, since all of the results were above the standard line, our 
samples did not cause cell death.  
The expression levels osteogenic encrypting for osteopontin (SPP1), bone sialoprotein 2 
(IBSP), and runt-related translation factor 2 (RUNX2) were measured after one, four, and seven 
days in growth and osteogenic media culture (Figure 2.8). All the data were analyzed by 
comparison between the initial expression value shown in the graph with a red line for each 
figure and the results obtained on the day seven. Also, if the results were higher than the initial 
value at day seven, it was defined as upregulated, which means it was increasing the gene 
expressing. On the other hand, if the result was less than the initial value, it was described as a 
downregulated. 
These results showed that there was a complex trend in a response to scaffold type (neat 
versus scaffold) and media type (p < 0.05). The samples in the osteogenic induction media had a 
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greater effect on osteogenic gene expression than the material type.  Statistical analysis 
demonstrated a significant effect of both the culture media and scaffold type (p < 0.05).  
 
Figure 2.8 The results of SSP1 expression 
 
Regardless of the medium type, the day one SPP1 expression for all of the samples was 
either higher than or equal to the initial gene expression value. However, the expression of SPP1 
for the samples in growth media was downregulated; the expression levels decreased slightly on 
day seven. The osteogenic groups (Figure 2.8) demonstrated the highest level of osteogenesis on 
day seven (p < 0.05). While SOM showed a slight decrease, COM groups did not demonstrate a 
decrease, and there were no significant differences between SOM and COM groups on day seven 
(p < 0.05). Neat and composite samples in the combination with osteogenic media had higher 
levels SPP1 expression than mineralized one (p < 0.05). The presence of the SSP1 expression in 
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the results suggests that this material can act as a structural substance since this gene regulates 
the biomineralization. 
 
Figure 2.9 The results of IBSP expression 
 
However, the trend in the SPP1 expression for samples in growth media was similar to 
the IBSP expression; the composite and neat samples in growth media did not promote the 
osteogenic responses. However, the IBSP expression level for neat and mineralized group in 
osteogenic media was up-regulated from day one to day seven and was higher than the other 
groups at day seven (p < 0.05) (Fig 2.9).  The expressions of IBSP are mostly observed in 
mineralized tissue and advances mineral formation in the bone. The high-level expression of 
IBSP results in the mineral and nodule formation and increase in the osteoblast related gene 





Figure 2.10 The results of RUNX2 expression 
 
Like the others, the RUNX2 expression of neat and composite samples in the growth 
media showed the similar pattern, they were downregulated. Osteogenic groups were 
upregulated (p<0.05) and there was no significant decrease in osteogenic groups for RUNX2 
expression. The mineralized and neat samples in growth media did not drive the osteogenic 
response while neat and composite samples in osteogenic media showed high osteogenic 
response. Increase in the expression of Runx-2 results in sufficient bone formation since RUNX2 
gene is viewed as a main controller of osteogenesis. For all the results, the samples in osteogenic 
media showed upregulated pattern for all gene expressions. Hence, samples in osteogenic media 
allows new bone formation. It can also be said that neat and mineralized samples in combination 






2.8. Future Works 
 
Although the studies were promising, more long term investigations must be done. 
Additional factor combinations or different dosage can be applied to explore their effects in 
future studies. Combining the growth factors with biomaterial is still being developed in other 
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